基于TFCE的非小细胞肺癌脑转移颅内空间分布频率的研究

doi:10.3969/j.issn.1009-976X.2022.02.008

摘要/Abstract

摘要： 目的基于MRI图像获取非小细胞肺癌脑转移发生频率的空间分布情况,获取肿瘤重点转移区域。方法根据纳入-排除标准,筛选非小细胞肺癌脑转移患者,获取MRI原始数据,手动勾画肿瘤区域,获取基于体素水平的肿瘤转移频率;使用TFCE非参数分析计算统计值,进行排列测试提取肿瘤区域中的重点区域。结果共35例患者纳入本研究,频率分布图显示同一体素的非小细胞肺癌脑转移病例数最大值为8,最高频率为22.86%,位于顶叶枕叶交界处后正中线,而非参数分析显示显著的簇位于侧脑室旁基底节区的灰白质交界处。结论非小细胞肺癌倾向于转移至后颅窝与基底节区,对脑转移癌MRI检查的分析可以为临床治疗过程提供辅助。

关键词: 脑转移瘤, 非小细胞肺癌, TFCE, 排列测试

Abstract: Objective By acquring spatial distribution of incidence rate of non-small cell lung cancer brain metastases based on MRI data, to determine the true signal area in brain metastatic areas. Methods According to the inclusion and exclusion criteria, patients with non-small cell lung cancer brain metastatic lesions were screened and included. We obtained their MRI data and segmented tumor area manually. After registration, we overlapped tumor regions together to calculate frequency of brain metastatic lesions. Using TFCE non-parametric analyses and permutation test to determine the true signal area. Results A total of 35 patients with non-small cell lung cancer brain metastases were included in this study. Frequency map showed highest frequency of non-small cell lung cancer was 22.86% and the highest metastatic number invoxel level was 8, which located in posterior midline of junction of parietal lobe and occipital lobe. The significant cluster of non-small cell lung cancer brain metastases was in grey-white matter border adjacent to ventricle and basal ganglia. Conclusion Non-small cell lung cancer brain metastases tend to locate in basal ganglia and posterior fossa and homogeneity exists between metastatic locations of different genders. Analyzing brain MRI data can provideassistance during the treatment process.

Key words: brain metastases, non-small cell lung cancer, TFCE, permutation test

中图分类号:

R734.2

李维, 杨淞然. 基于TFCE的非小细胞肺癌脑转移颅内空间分布频率的研究[J]. 岭南现代临床外科, 2022, 22(02): 163-167.

LI Wei, YANG Song-ran. Research on intracranial spatial distribution of NSCLC brain metastatic based on TFCE[J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 163-167.

参考文献

[1] Cagney DN, Martin AM, Catalano PJ, et al.Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study[J]. Neuro Oncol, 2017, 19(11): 1511-1521.
[2] Friston KJ, Holmes A, Poline JB, et al.Detecting activations in PET and fMRI: levels of inference and power[J]. Neuroimage, 1996, 4(3 Pt 1): 223-235.
[3] Smith SM, Nichols TE.Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference[J]. Neuroimage, 2009, 44(1): 83-98.
[4] Han H, Glenn AL, Dawson KJ.Evaluating Alternative Correction Methods for Multiple Comparison in Functional Neuroimaging Research[J]. Brain Sci, 2019, 9(8):198.
[5] Arco JE, González-García C, Díaz-Gutiérrez P, et al.Influence of activation pattern estimates and statistical significance tests in fMRI decoding analysis[J]. J Neurosci Methods, 2018, 308: 248-260.
[6] Ramasamy DP, Ramanathan M, Cox JL, et al.Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study[J]. Pathophysiology, 2011, 18(1): 53-60.
[7] Olvera RL, Glahn DC, O′Donnell L, et al. Cortical Volume Alterations in Conduct Disordered Adolescents with and without Bipolar Disorder[J]. J Clin Med, 2014, 3(2): 416-431.
[8] Mallas E, Carletti F, Chaddock CA, et al.The impact of CACNA1C gene, and its epistasis with ZNF804A, on white matter microstructure in health, schizophrenia and bipolar disorder1[J]. Genes Brain Behav, 2017, 16(4): 479-488.
[9] Incekara F, van der Voort SR, Dubbink HJ, et al. Topographical mapping of 436 newly diagnosed IDH wildtype glioblastoma with vs. without MGMT promoter methylation[J]. Front Oncol, 2020, 10: 596.
[10] Winkler AM, Ridgway GR, Webster MA, et al.Permutation inference for the general linear model[J]. Neuroimage, 2014, 92: 381-397.
[11] John L, Hugh D.Why Permutation Tests are Superior to t and F Tests in Biomedical Research[J]. The Am Stat, 1998, 52(2): 127-132.
[12] Fortunato Pesarin, Luigi Salmaso.Permutation Tests for Complex Data[M]. Chichester (UK): John Wiley & Sons, 2010.
[13] Takano K, Kinoshita M, Takagaki M, et al.Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor[J]. Neuro Oncol, 2016, 18(5): 716-724.
[14] Quattrocchi CC, Errante Y, Gaudino C, et al.Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients[J]. J Neurooncol, 2012, 110(1): 79-87.
[15] Yanagihara TK, Lee A, Wang TJC.Quantitative Analysis of the Spatial Distribution of Metastatic Brain Lesions[J]. Tomography, 2017, 3(1): 16-22.
[16] Mampre D, Ehresman J, Alvarado-Estrada K, et al.Propensity for different vascular distributions and cerebral edema of intraparenchymal brain metastases from different primary cancers[J]. J Neurooncol, 2019, 143(1): 115-122.
[17] Donnem T, Hu J, Ferguson M, et al.Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?[J]. Cancer Med, 2013, 2(4): 427-436.
[18] Berghoff AS, Ilhan-Mutlu A, Dinhof C, et al.Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases[J]. Neuropathol Appl Neurobiol, 2015, 41(2): e41-55.
[19] Helfrich I, Scheffrahn I, Bartling S, et al.Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma[J]. J Exp Med, 2010, 207(3): 491-503.
[20] Budde MD, Gold E, Jordan EK, et al.Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI[J]. Clin Exp Metastasis, 2012, 29(1): 51-62.
[21] Adighibe O, Micklem K, Campo L, et al.Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions[J]. Br J Cancer, 2006, 94(8): 1176-1179.
[22] Ito H, Yokoyama I, Iida H, et al.Regional differences in cerebral vascular response to PaCO2 changes in humans measured by positron emission tomography[J]. J Cereb Blood Flow Metab, 2000, 20(8): 1264-1270.
[23] Cavaglia M, Dombrowski SM, Drazba J, et al.Regional variation in brain capillary density and vascular response to ischemia[J]. Brain Res, 2001, 910(1-2): 81-93.
[24] van Laar PJ, Hendrikse J, Golay X, et al. In vivo flow territory mapping of major brain feeding arteries[J]. Neuroimage, 2006, 29(1): 136-144.
[25] Hendrikse J, van der Grond J, Lu H, et al. Flow territory mapping of the cerebral arteries with regional perfusion MRI[J]. Stroke, 2004, 35(4): 882-887.
[26] Gori S, Rimondini S, De Angelis V, et al.Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors[J]. Oncologist, 2007, 12(7): 766-773.
[27] Bendell JC, Domchek SM, Burstein HJ, et al.Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma[J]. Cancer, 2003, 97(12): 2972-2977.
[28] Foulkes WD, Smith IE, Reis-Filho JS.Triple-negative breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
[29] Müller A, Homey B, Soto H, et al.Involvement of chemokine receptors in breast cancer metastasis[J]. Nature, 2001, 410(6824): 50-56.
[30] Achrol AS, Rennert RC, Anders C, et al.Brain metastases[J]. Nat Rev Dis Primers, 2019, 5(1): 5.